dc.contributor.advisor | Hutt, Peter Barton | en_US |
dc.contributor.author | Guerra, Marcelo | en_US |
dc.date.accessioned | 2012-12-07T15:17:15Z | |
dc.date.issued | 2004 | en_US |
dc.identifier.citation | The FDA’s Role in the Development of Bioterrorist Countermeasures (2004 Third Year Paper) | en |
dc.identifier.uri | http://nrs.harvard.edu/urn-3:HUL.InstRepos:10015278 | |
dc.description.abstract | As the agency that approves drug products used to treat bioterrorist diseases, the FDA plays a
significant role in the domestic preparation against a bioterrorist attack. The changes that occurred at the
agency in response the AIDS and cancer crises of the 1980’s have served as a blueprint for the changes
made in response to the terrorist threat. These changes, often desirable but sometimes not, push even
further the agency’s role as a collaborator in drug development. The paper investigates the threat of a
biological weapon attack and the changes to the drug approval process that this threat has prompted. | en |
dc.language.iso | en_US | en |
dash.license | LAA | en_US |
dc.subject | Food and Drug Law | en |
dc.subject | bioterrorism | en |
dc.title | The FDA’s Role in the Development of Bioterrorist Countermeasures | en |
dc.type | Paper (for course/seminar/workshop) | en_US |
dc.date.available | 2012-12-07T15:17:15Z | |
dash.authorsordered | false | |